Anhui Huaheng Biotech Passes Hong Kong Stock Exchange Hearing on June 22, First to Commercialize Amino Acid Fermentation

According to Hong Kong Exchanges and Clearing, Anhui Huaheng Biotechnology Co., Ltd. (688639.SH) passed its main board listing hearing on June 22, with Huatai International as its sole sponsor. The company is the world's first to commercialize anaerobic fermentation technology for producing amino acids including L-alanine and L-valine. As of 2024, Huaheng holds the global number-one market share for both L-alanine and L-valine by revenue. As of December 31, 2025, the company has established stable long-term partnerships with over 815 clients across 89 countries in Asia, Europe, and the Americas. The company's product portfolio includes amino acids, vitamins, and bio-based materials, serving industries such as animal nutrition, cosmetics, food and beverages, and plant nutrition.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments